Skip to main content

Table 2 Sensitivity to gefitinib treatment for different NSCLC cells

From: miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

Cell lines

Histology

EGFR mutation

IC50 of gefitinib (μM)

PC-9

AD

E746-A750 del

0.047 ± 0.012

NCI-H820

AD

E746-E749 del

2.783 ± 0.854

NCI-H2170

SQ

WT

4.254 ± 0.752

A549

AD

WT

9.172 ± 1.228

NCI-H1650

AD

E746-A750 del

10.473 ± 2.164

NCI-H1993

AD

WT

16.432 ± 0.965

NCI-H2126

LC

WT

23.179 ± 2.843

NCI-H1975

AD

L858R

26.748 ± 3.386

NCI-H1299

LC

WT

28.637 ± 2.512

NCI-H1648

AD

WT

38.425 ± 1.838

NCI-H1703

SQ

WT

41.258 ± 5.217

NCI-H2347

AD

WT

62.417 ± 4.658

  1. NSCLC non-small cell lung carcinoma, AD adenocarcinoma, SQ squamous cell carcinoma, LC large cell carcinoma, WT wild type